BLRX PE Ratio & Valuation, Is BLRX Overvalued

Historical Valuation

BioLine RX Ltd (BLRX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 5.02 is considered Undervalued compared with the five-year average of -1.65. The fair price of BioLine RX Ltd (BLRX) is between 157.36 to 158.61 according to relative valuation method. Compared to the current price of 2.61 USD , BioLine RX Ltd By Undervalued By 98.34%.

Relative Value

Fair Zone

157.36-158.61

Current Price：2.61

98.34%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is BioLine RX Ltd (BLRX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

BioLine RX Ltd (BLRX) has a current Price-to-Book (P/B) ratio of 374.28. Compared to its 3-year average P/B ratio of 141.25, the current P/B ratio is approximately 164.97% higher. Relative to its 5-year average P/B ratio of 84.89, the current P/B ratio is about 340.90% higher. BioLine RX Ltd (BLRX) has a Forward Free Cash Flow (FCF) yield of approximately -109.73%. Compared to its 3-year average FCF yield of -97.88%, the current FCF yield is approximately 12.10% lower. Relative to its 5-year average FCF yield of -72.88%, the current FCF yield is about 50.57% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for BLRX competitors is 1307.03, providing a benchmark for relative valuation. BioLine RX Ltd Corp (BLRX.O) exhibits a P/S ratio of 5.02, which is -99.62% above the industry average. Given its robust revenue growth of -91.36%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of BLRX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of BLRX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is BLRX currently overvalued or undervalued?

What is BioLine RX Ltd (BLRX) fair value?

BLRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of BioLine RX Ltd (BLRX) is between 157.36 to 158.61 according to relative valuation method.

How does BLRX's valuation metrics compare to the industry average?

The average P/S ratio for BLRX's competitors is 1307.03, providing a benchmark for relative valuation. BioLine RX Ltd Corp (BLRX) exhibits a P/S ratio of 5.02, which is -99.62% above the industry average. Given its robust revenue growth of -91.36%, this premium appears unsustainable.

What is the current P/B ratio for BioLine RX Ltd (BLRX) as of Mar 12 2026?

As of Mar 12 2026, BioLine RX Ltd (BLRX) has a P/B ratio of 374.28. This indicates that the market values BLRX at 374.28 times its book value.

What is the current FCF Yield for BioLine RX Ltd (BLRX) as of Mar 12 2026?

As of Mar 12 2026, BioLine RX Ltd (BLRX) has a FCF Yield of -109.73%. This means that for every dollar of BioLine RX Ltd's market capitalization, the company generates -109.73 cents in free cash flow.

What is the current Forward P/E ratio for BioLine RX Ltd (BLRX) as of Mar 12 2026?

As of Mar 12 2026, BioLine RX Ltd (BLRX) has a Forward P/E ratio of -1.35. This means the market is willing to pay $-1.35 for every dollar of BioLine RX Ltd's expected earnings over the next 12 months.

What is the current Forward P/S ratio for BioLine RX Ltd (BLRX) as of Mar 12 2026?

As of Mar 12 2026, BioLine RX Ltd (BLRX) has a Forward P/S ratio of 5.02. This means the market is valuing BLRX at $5.02 for every dollar of expected revenue over the next 12 months.

BLRX Valuation